Improved survival with ipilimumab in patients with metastatic melanoma

New England Journal of Medicine

Volumn 363, Issue 8, 2010, Pages 711-723

  Hodi, F Stephen ^a   O'Day, Steven J ^c   McDermott, David F ^b   Weber, Robert W ^d   Sosman, Jeffrey A ^e   Haanen, John B ^f   Gonzalez, Rene ^h   Robert, Caroline ⁱ   Schadendorf, Dirk ^j   Hassel, Jessica C ^k   Akerley, Wallace ^m   Van Den Eertwegh, Alfons J M ^g   Lutzky, Jose ⁿ   Lorigan, Paul ^o   Vaubel, Julia M ^j   Linette, Gerald P ^q   Hogg, David ^r   Ottensmeier, Christian H ^p   Lebbé, Celeste ^s   Peschel, Christian ^l   Quirt, Ian ^r   Clark, Joseph I ^t   Wolchok, Jedd D ^u   Weber, Jeffrey S ^v   Tian, Jason ^w   Yellin, Michael J ^w   Nichol, Geoffrey M ^w   Hoos, Axel ^x   Urba, Walter J ^y   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c Angeles Clinic and Research Institute   (United States)

^d Breast Cancer Consultation Service St Mary Hospital and Medical Center Pathology   (United States)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^f NETHERLANDS CANCER INSTITUTE   (Netherlands)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^h UNIVERSITY OF COLORADO CANCER CENTER   (United States)

ⁱ INSTITUT GUSTAVE ROUSSY   (France)

^j UNIVERSITY HOSPITAL ESSEN   (Germany)

^k UNIVERSITY OF MANNHEIM   (Germany)

^l TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^m UNIVERSITY OF UTAH   (United States)

ⁿ Mount Sinai Comprehensive Cancer Center   (United States)

^o CHRISTIE HOSPITAL   (United Kingdom)

^p UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^q WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^r PRINCESS MARGARET HOSPITAL   (Canada)

^s SAINT LOUIS HOSPITAL   (France)

^t LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^u MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^v H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^w MEDAREX INC   (United States)

^x BRISTOL MYERS SQUIBB   (United States)

^y EARLE A CHILES RESEARCH INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CARBOPLATIN; CORTICOSTEROID; CORTICOTROPIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; FOTEMUSTINE; GLYCOPROTEIN GP 100; HLA A ANTIGEN; INTERLEUKIN 2; IPILIMUMAB; PEPTIDE VACCINE; TEMOZOLOMIDE; THYROTROPIN;

ABDOMINAL PAIN; ADRENAL INSUFFICIENCY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT; CANCER FATIGUE; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL TRIAL; COLITIS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; COUGHING; CYTOTOXIC T LYMPHOCYTE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG FEVER; DRUG INDUCED HEADACHE; FEMALE; HAZARD RATIO; HEPATITIS; HUMAN; HYPOPHYSITIS; HYPOPITUITARISM; HYPOTHYROIDISM; INJECTION SITE REACTION; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTATIC MELANOMA; OVERALL SURVIVAL; PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROCTOCOLITIS; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RECTAL PAIN; SIDE EFFECT; THYROTROPIN BLOOD LEVEL; TREATMENT RESPONSE; VITILIGO; VOMITING;

EID: 77954801079     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1003466     Document Type: Article

References (38)

1. American Cancer Society. Cancer facts & figures 2009. (Accessed June 4, 2010, at http://www.cancer.org/downloads/STT/500809web.pdf.)
2. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature 2007;445:851-7. (Pubitemid 46309849)
3. Lens MB, Dawes M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol 2004;150:179-85. (Pubitemid 38352453)
4. World Health Organization. Skin cancers. (Accessed June 4, 2010, at http://www.who.int/uv/faq/skincancer/en/index1.html.)
5. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004;351:998-1012. [Erratum, N Engl J Med 2004;351:2461.]
6. Agarwala SS. Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther 2009;9:587-95.
7. Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer 2004;40:1825-36.
8. Petrella T, Quirt I, Verma S, Haynes AE, Charette M, Bak K. Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review. Cancer Treat Rev 2007;33:484-96. (Pubitemid 47333669)
9. Trinh VA. Current management of metastatic melanoma. Am J Health Syst Pharm 2008;65:Suppl 9:S3-S8.
10. Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007;7:95-106. (Pubitemid 46160986)
11. O'Day SJ, Hamid O, Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer 2007;110:2614-27. (Pubitemid 350250330)
12. Fong L, Small EJ. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol 2008;26:5275-83.
13. Robert C, Ghiringhelli F. What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma? Oncologist 2009;14:848-61.
14. Weber J. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother 2009;58:823-30.
15. Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009;15:5591-8.
16. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010;11:155-64.
17. O'Day SJ, Maio M, Chiarion-Sileni V, et al. Efficacy and safety of ipilimumab monotherapy in patients with previously treated, advanced melanoma: a multicenter, single-arm phase II study. Ann Oncol 2010 February 10 (Epub ahead of print).
18. Maker AV, Phan GQ, Attia P, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 2005;12:1005-16.
19. Agarwala SS. Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma. Melanoma Res 2010;20:1-10.
20. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005;23:6043-53.
21. Downey SG, Klapper JA, Smith FO, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007;13:6681-8.
22. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15.
23. Schwartzentruber DJ, Lawson D, Richards J, et al. A phase III multi-institutional randomized study of immunization with the gp100:209-217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma. J Clin Oncol 2009;27:Suppl:463s. abstract.
24. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
25. ClinicalTrials.gov. Dacarbazine and ipilimumab vs. dacarbazine with placebo in untreated unresectable stage III or IV melanoma. (Accessed June 4, 2010, at http://www.clinicaltrials.gov/ct/show/NCT00324155.)
26. James K, Eisenhauer E, Christian M, et al. Measuring response in solid tumors: unidimensional versus bidimensional measurement. J Natl Cancer Inst 1999;91:523-8. (Pubitemid 29157060)
27. Korn EL, Liu PY, Lee SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008;26:527-34.
28. Bedikian AY, Johnson MM, Warneke CL, et al. Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma. Cancer Invest 2008;26:624-33.
29. Barrow C, Browning J, MacGregor D, et al. Tumor antigen expression in melanoma varies according to antigen and stage. Clin Cancer Res 2006;12:764-71. (Pubitemid 43259856)
30. Morton DL, Mozzillo N, Thompson JF, et al. An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. J Clin Oncol 2007;25:Suppl:474s. abstract.
31. Eggermont AM, Suciu S, Ruka W, et al. EORTC 18961: post-operative adjuvant ganglioside GM2-KLH21 vaccination treatment vs observation in stage II (T3-T4N0M0) melanoma: 2nd interim analysis led to an early disclosure of the results. J Clin Oncol 2008;26:Suppl:484s. abstract.
32. Testori A, Richards J, Whitman E, et al. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma. J Clin Oncol 2008;26:955-62.
33. Sosman JA, Unger JM, Liu PY, et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J Clin Oncol 2002;20:2067-75.
34. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009;15:7412-20.
35. Eisen T, Trefzer U, Hamilton A, et al. Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. Cancer 2010;116:146-54.
36. Hauschild A, Agarwala SS, Trefzer U, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009;27:2823-30.
37. Weber J. Anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 2007;12:864-72.
38. Lin R, Yellin MJ, Lowy I, Safferman A, Chin K, Ibrahim R. An analysis of the effectiveness of specific guidelines for the management of ipilimumab-mediated diarrhea/colitis: prevention of gastrointestinal perforation and/or colectomy. J Clin Oncol 2008;26:Suppl:497s. abstract.